-
1
-
-
77952994160
-
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver
-
Amin D.N., Sergina N., Ahuja D., McMahon M., Blair J.A., Wang D., Hann B., Koch K.M., Shokat K.M., Moasser M.M. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med. 2010, 2:ra7.
-
(2010)
Sci. Transl. Med.
, vol.2
-
-
Amin, D.N.1
Sergina, N.2
Ahuja, D.3
McMahon, M.4
Blair, J.A.5
Wang, D.6
Hann, B.7
Koch, K.M.8
Shokat, K.M.9
Moasser, M.M.10
-
2
-
-
34447506658
-
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
-
Ancrile B., Lim K.H., Counter C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007, 21:1714-1719.
-
(2007)
Genes Dev.
, vol.21
, pp. 1714-1719
-
-
Ancrile, B.1
Lim, K.H.2
Counter, C.M.3
-
3
-
-
3843084078
-
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
-
Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., Flanagan A., Teague J., Futreal P.A., Stratton M.R., Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 2004, 91:355-358.
-
(2004)
Br. J. Cancer
, vol.91
, pp. 355-358
-
-
Bamford, S.1
Dawson, E.2
Forbes, S.3
Clements, J.4
Pettett, R.5
Dogan, A.6
Flanagan, A.7
Teague, J.8
Futreal, P.A.9
Stratton, M.R.10
Wooster, R.11
-
4
-
-
0036857484
-
A scaleable synthesis of BAY 43-9006: a potent Raf kinase inhibitor for the treatment of cancer
-
Bankston D., Dumas J., Natero R., Riedl B., Monahan M.-K., Sibley R. A scaleable synthesis of BAY 43-9006: a potent Raf kinase inhibitor for the treatment of cancer. Org. Process Res. Dev. 2001, 6:777-781.
-
(2001)
Org. Process Res. Dev.
, vol.6
, pp. 777-781
-
-
Bankston, D.1
Dumas, J.2
Natero, R.3
Riedl, B.4
Monahan, M.-K.5
Sibley, R.6
-
5
-
-
22144495367
-
NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry
-
Bassermann F., von Klitzing C., Münch S., Bai R.Y., Kawaguchi H., Morris S.W., Peschel C., Duyster J. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 2005, 122:45-57.
-
(2005)
Cell
, vol.122
, pp. 45-57
-
-
Bassermann, F.1
von Klitzing, C.2
Münch, S.3
Bai, R.Y.4
Kawaguchi, H.5
Morris, S.W.6
Peschel, C.7
Duyster, J.8
-
6
-
-
84890644513
-
Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an invivo model of childhood astrocytoma
-
Bid H.K., Kibler A., Phelps D.A., Manap S., Xiao L., Lin J., Capper D., Oswald D., Geier B., DeWire M., et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an invivo model of childhood astrocytoma. Clin. Cancer Res. 2013, 19:6716-6729.
-
(2013)
Clin. Cancer Res.
, vol.19
, pp. 6716-6729
-
-
Bid, H.K.1
Kibler, A.2
Phelps, D.A.3
Manap, S.4
Xiao, L.5
Lin, J.6
Capper, D.7
Oswald, D.8
Geier, B.9
DeWire, M.10
-
7
-
-
77957596001
-
Discovery of pyrrolopyrimidine inhibitors of Akt
-
Blake J.F., Kallan N.C., Xiao D., Xu R., Bencsik J.R., Skelton N.J., Spencer K.L., Mitchell I.S., Woessner R.D., Gloor S.L., et al. Discovery of pyrrolopyrimidine inhibitors of Akt. Bioorg. Med. Chem. Lett. 2010, 20:5607-5612.
-
(2010)
Bioorg. Med. Chem. Lett.
, vol.20
, pp. 5607-5612
-
-
Blake, J.F.1
Kallan, N.C.2
Xiao, D.3
Xu, R.4
Bencsik, J.R.5
Skelton, N.J.6
Spencer, K.L.7
Mitchell, I.S.8
Woessner, R.D.9
Gloor, S.L.10
-
8
-
-
79955472800
-
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK
-
Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., Shokat K.M., Barford D. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 2011, 472:366-369.
-
(2011)
Nature
, vol.472
, pp. 366-369
-
-
Brennan, D.F.1
Dar, A.C.2
Hertz, N.T.3
Chao, W.C.4
Burlingame, A.L.5
Shokat, K.M.6
Barford, D.7
-
9
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
BRIM-3 Study Group
-
Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N.Engl. J. Med. 2011, 364:2507-2516. BRIM-3 Study Group.
-
(2011)
N.Engl. J. Med.
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
Dummer, R.7
Garbe, C.8
Testori, A.9
Maio, M.10
-
10
-
-
0033565832
-
Role of accurate mass measurement (+/- 10 ppm) in protein identification strategies employing MS or MS/MS and database searching
-
Clauser K.R., Baker P., Burlingame A.L. Role of accurate mass measurement (+/- 10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal. Chem. 1999, 71:2871-2882.
-
(1999)
Anal. Chem.
, vol.71
, pp. 2871-2882
-
-
Clauser, K.R.1
Baker, P.2
Burlingame, A.L.3
-
11
-
-
84861863158
-
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
-
Corcoran R.B., Ebi H., Turke A.B., Coffee E.M., Nishino M., Cogdill A.P., Brown R.D., Della Pelle P., Dias-Santagata D., Hung K.E., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012, 2:227-235.
-
(2012)
Cancer Discov.
, vol.2
, pp. 227-235
-
-
Corcoran, R.B.1
Ebi, H.2
Turke, A.B.3
Coffee, E.M.4
Nishino, M.5
Cogdill, A.P.6
Brown, R.D.7
Della Pelle, P.8
Dias-Santagata, D.9
Hung, K.E.10
-
12
-
-
84879474335
-
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia
-
Cooper M.J., Cox N.J., Zimmerman E.I., Dewar B.J., Duncan J.S., Whittle M.C., Nguyen T.A., Jones L.S., Ghose Roy S., Smalley D.M., et al. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. PLoS One 2013, 8:e66755.
-
(2013)
PLoS One
, vol.8
-
-
Cooper, M.J.1
Cox, N.J.2
Zimmerman, E.I.3
Dewar, B.J.4
Duncan, J.S.5
Whittle, M.C.6
Nguyen, T.A.7
Jones, L.S.8
Ghose Roy, S.9
Smalley, D.M.10
-
13
-
-
48349138726
-
Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle
-
Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Körner R., Greff Z., Kéri G., Stemmann O., Mann M. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol. Cell 2008, 31:438-448.
-
(2008)
Mol. Cell
, vol.31
, pp. 438-448
-
-
Daub, H.1
Olsen, J.V.2
Bairlein, M.3
Gnad, F.4
Oppermann, F.S.5
Körner, R.6
Greff, Z.7
Kéri, G.8
Stemmann, O.9
Mann, M.10
-
14
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
Teague, J.7
Woffendin, H.8
Garnett, M.J.9
Bottomley, W.10
-
15
-
-
84859765844
-
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer
-
Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., Johnson N.L., Granger D.A., Jordan N.V., Darr D.B., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
-
(2012)
Cell
, vol.149
, pp. 307-321
-
-
Duncan, J.S.1
Whittle, M.C.2
Nakamura, K.3
Abell, A.N.4
Midland, A.A.5
Zawistowski, J.S.6
Johnson, N.L.7
Granger, D.A.8
Jordan, N.V.9
Darr, D.B.10
-
16
-
-
84864371119
-
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
-
Falchook G.S., Lewis K.D., Infante J.R., Gordon M.S., Vogelzang N.J., DeMarini D.J., Sun P., Moy C., Szabo S.A., Roadcap L.T., et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012, 13:782-789.
-
(2012)
Lancet Oncol.
, vol.13
, pp. 782-789
-
-
Falchook, G.S.1
Lewis, K.D.2
Infante, J.R.3
Gordon, M.S.4
Vogelzang, N.J.5
DeMarini, D.J.6
Sun, P.7
Moy, C.8
Szabo, S.A.9
Roadcap, L.T.10
-
17
-
-
84873024023
-
The dynamic nature of the kinome
-
Graves L.M., Duncan J.S., Whittle M.C., Johnson G.L. The dynamic nature of the kinome. Biochem. J. 2013, 450:1-8.
-
(2013)
Biochem. J.
, vol.450
, pp. 1-8
-
-
Graves, L.M.1
Duncan, J.S.2
Whittle, M.C.3
Johnson, G.L.4
-
18
-
-
74849109743
-
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
-
Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
-
(2010)
Cell
, vol.140
, pp. 209-221
-
-
Heidorn, S.J.1
Milagre, C.2
Whittaker, S.3
Nourry, A.4
Niculescu-Duvas, I.5
Dhomen, N.6
Hussain, J.7
Reis-Filho, J.S.8
Springer, C.J.9
Pritchard, C.10
Marais, R.11
-
19
-
-
0041677606
-
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
-
Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
-
(2003)
Biochem. J.
, vol.374
, pp. 1-20
-
-
Heinrich, P.C.1
Behrmann, I.2
Haan, S.3
Hermanns, H.M.4
Müller-Newen, G.5
Schaper, F.6
-
20
-
-
84868314587
-
Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M
-
Illert A.L., Zech M., Moll C., Albers C., Kreutmair S., Peschel C., Bassermann F., Duyster J. Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M. J.Biol. Chem. 2012, 287:37997-38005.
-
(2012)
J.Biol. Chem.
, vol.287
, pp. 37997-38005
-
-
Illert, A.L.1
Zech, M.2
Moll, C.3
Albers, C.4
Kreutmair, S.5
Peschel, C.6
Bassermann, F.7
Duyster, J.8
-
21
-
-
84871720411
-
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
-
Jänne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C., Franke F.A., Grinsted L., Zazulina V., Smith P., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013, 14:38-47.
-
(2013)
Lancet Oncol.
, vol.14
, pp. 38-47
-
-
Jänne, P.A.1
Shaw, A.T.2
Pereira, J.R.3
Jeannin, G.4
Vansteenkiste, J.5
Barrios, C.6
Franke, F.A.7
Grinsted, L.8
Zazulina, V.9
Smith, P.10
-
22
-
-
84859471412
-
Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies
-
Kudchadkar R., Paraiso K.H., Smalley K.S. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J. 2012, 18:124-131.
-
(2012)
Cancer J.
, vol.18
, pp. 124-131
-
-
Kudchadkar, R.1
Paraiso, K.H.2
Smalley, K.S.3
-
23
-
-
84869067183
-
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
-
Lito P., Pratilas C.A., Joseph E.W., Tadi M., Halilovic E., Zubrowski M., Huang A., Wong W.L., Callahan M.K., Merghoub T., et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012, 22:668-682.
-
(2012)
Cancer Cell
, vol.22
, pp. 668-682
-
-
Lito, P.1
Pratilas, C.A.2
Joseph, E.W.3
Tadi, M.4
Halilovic, E.5
Zubrowski, M.6
Huang, A.7
Wong, W.L.8
Callahan, M.K.9
Merghoub, T.10
-
24
-
-
84877631604
-
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas
-
Montero-Conde C., Ruiz-Llorente S., Dominguez J.M., Knauf J.A., Viale A., Sherman E.J., Ryder M., Ghossein R.A., Rosen N., Fagin J.A. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013, 3:520-533.
-
(2013)
Cancer Discov.
, vol.3
, pp. 520-533
-
-
Montero-Conde, C.1
Ruiz-Llorente, S.2
Dominguez, J.M.3
Knauf, J.A.4
Viale, A.5
Sherman, E.J.6
Ryder, M.7
Ghossein, R.A.8
Rosen, N.9
Fagin, J.A.10
-
25
-
-
84887425345
-
Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling
-
Nan X., Collisson E.A., Lewis S., Huang J., Tamgüney T.M., Liphardt J.T., McCormick F., Gray J.W., Chu S. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc. Natl. Acad. Sci. USA 2013, 110:18519-18524.
-
(2013)
Proc. Natl. Acad. Sci. USA
, vol.110
, pp. 18519-18524
-
-
Nan, X.1
Collisson, E.A.2
Lewis, S.3
Huang, J.4
Tamgüney, T.M.5
Liphardt, J.T.6
McCormick, F.7
Gray, J.W.8
Chu, S.9
-
26
-
-
0042030813
-
Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)
-
Ouyang T., Bai R.Y., Bassermann F., von Klitzing C., Klumpen S., Miething C., Morris S.W., Peschel C., Duyster J. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J.Biol. Chem. 2003, 278:30028-30036.
-
(2003)
J.Biol. Chem.
, vol.278
, pp. 30028-30036
-
-
Ouyang, T.1
Bai, R.Y.2
Bassermann, F.3
von Klitzing, C.4
Klumpen, S.5
Miething, C.6
Morris, S.W.7
Peschel, C.8
Duyster, J.9
-
27
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
-
Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
-
(2010)
Nature
, vol.464
, pp. 427-430
-
-
Poulikakos, P.I.1
Zhang, C.2
Bollag, G.3
Shokat, K.M.4
Rosen, N.5
-
28
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
Sun, C.2
Huang, S.3
Di Nicolantonio, F.4
Salazar, R.5
Zecchin, D.6
Beijersbergen, R.L.7
Bardelli, A.8
Bernards, R.9
-
29
-
-
63149194964
-
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
-
Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 2009, 106:4519-4524.
-
(2009)
Proc. Natl. Acad. Sci. USA
, vol.106
, pp. 4519-4524
-
-
Pratilas, C.A.1
Taylor, B.S.2
Ye, Q.3
Viale, A.4
Sander, C.5
Solit, D.B.6
Rosen, N.7
-
30
-
-
33644786244
-
Regulation and role of Raf-1/B-Raf heterodimerization
-
Rushworth L.K., Hindley A.D., O'Neill E., Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 2006, 26:2262-2272.
-
(2006)
Mol. Cell. Biol.
, vol.26
, pp. 2262-2272
-
-
Rushworth, L.K.1
Hindley, A.D.2
O'Neill, E.3
Kolch, W.4
-
31
-
-
84861178173
-
Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation
-
Schilling B., Rardin M.J., MacLean B.X., Zawadzka A.M., Frewen B.E., Cusack M.P., Sorensen D.J., Bereman M.S., Jing E., Wu C.C., et al. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol. Cell. Proteomics 2012, 11:202-214.
-
(2012)
Mol. Cell. Proteomics
, vol.11
, pp. 202-214
-
-
Schilling, B.1
Rardin, M.J.2
MacLean, B.X.3
Zawadzka, A.M.4
Frewen, B.E.5
Cusack, M.P.6
Sorensen, D.J.7
Bereman, M.S.8
Jing, E.9
Wu, C.C.10
-
32
-
-
0029011218
-
The MAPK signaling cascade
-
Seger R., Krebs E.G. The MAPK signaling cascade. FASEB J. 1995, 9:726-735.
-
(1995)
FASEB J.
, vol.9
, pp. 726-735
-
-
Seger, R.1
Krebs, E.G.2
-
33
-
-
3142676436
-
Overriding imatinib resistance with a novel ABL kinase inhibitor
-
Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
-
(2004)
Science
, vol.305
, pp. 399-401
-
-
Shah, N.P.1
Tran, C.2
Lee, F.Y.3
Chen, P.4
Norris, D.5
Sawyers, C.L.6
-
34
-
-
70449995469
-
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
-
Sos M.L., Fischer S., Ullrich R., Peifer M., Heuckmann J.M., Koker M., Heynck S., Stückrath I., Weiss J., Fischer F., et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc. Natl. Acad. Sci. USA 2009, 106:18351-18356.
-
(2009)
Proc. Natl. Acad. Sci. USA
, vol.106
, pp. 18351-18356
-
-
Sos, M.L.1
Fischer, S.2
Ullrich, R.3
Peifer, M.4
Heuckmann, J.M.5
Koker, M.6
Heynck, S.7
Stückrath, I.8
Weiss, J.9
Fischer, F.10
-
35
-
-
69049087175
-
Tuning a three-component reaction for trapping kinase substrate complexes
-
Statsuk A.V., Maly D.J., Seeliger M.A., Fabian M.A., Biggs W.H., Lockhart D.J., Zarrinkar P.P., Kuriyan J., Shokat K.M. Tuning a three-component reaction for trapping kinase substrate complexes. J.Am. Chem. Soc. 2008, 130:17568-17574.
-
(2008)
J.Am. Chem. Soc.
, vol.130
, pp. 17568-17574
-
-
Statsuk, A.V.1
Maly, D.J.2
Seeliger, M.A.3
Fabian, M.A.4
Biggs, W.H.5
Lockhart, D.J.6
Zarrinkar, P.P.7
Kuriyan, J.8
Shokat, K.M.9
-
36
-
-
21744448078
-
An unbiased cell morphology-based screen for new, biologically active small molecules
-
Tanaka M., Bateman R., Rauh D., Vaisberg E., Ramachandani S., Zhang C., Hansen K.C., Burlingame A.L., Trautman J.K., Shokat K.M., Adams C.L. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 2005, 3:e128.
-
(2005)
PLoS Biol.
, vol.3
-
-
Tanaka, M.1
Bateman, R.2
Rauh, D.3
Vaisberg, E.4
Ramachandani, S.5
Zhang, C.6
Hansen, K.C.7
Burlingame, A.L.8
Trautman, J.K.9
Shokat, K.M.10
Adams, C.L.11
-
37
-
-
84864286442
-
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
-
Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
-
(2012)
Nature
, vol.487
, pp. 505-509
-
-
Wilson, T.R.1
Fridlyand, J.2
Yan, Y.3
Penuel, E.4
Burton, L.5
Chan, E.6
Peng, J.7
Lin, E.8
Wang, Y.9
Sosman, J.10
-
38
-
-
84897950139
-
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit
-
Zhu Z., Aref A.R., Cohoon T.J., Barbie T.U., Imamura Y., Yang S., Moody S.E., Shen R.R., Schinzel A.C., Thai T.C., et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014, 4:452-465.
-
(2014)
Cancer Discov.
, vol.4
, pp. 452-465
-
-
Zhu, Z.1
Aref, A.R.2
Cohoon, T.J.3
Barbie, T.U.4
Imamura, Y.5
Yang, S.6
Moody, S.E.7
Shen, R.R.8
Schinzel, A.C.9
Thai, T.C.10
|